Agoracom Blog Home

Posts Tagged ‘Hemp’

« Older Entries
Newer Entries »

Marijuana Company of America $MCOA Announces New hempSMART(TM) Website and Sales Platform $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:33 AM on Tuesday, December 11th, 2018
  • Announced the launch of a new corporate hempSMART™ website and marketing platform for its associates
  • By implementing this new associate platform, hempSMART’s customers now have the ability to subscribe monthly to our products creating a pathway to generate an annuity stream of monthly reoccurring revenue with minimal follow up.

Escondido, California–(December 11, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the launch of a new corporate hempSMART™ website and marketing platform for its associates.

By implementing this new associate platform, hempSMART’s customers now have the ability to subscribe monthly to our products creating a pathway to generate an annuity stream of monthly reoccurring revenue with minimal follow up. Since Q3, the Company has already seen an increase in associate signups with the new marketing platform and it is expected that Q4 of 2018 will feature the highest generated revenue of the Company’s history.

The new hempSMART platform is focused on incentivizing our current and future associates to take full advantage of our newly structured compensation plan. MCOA anticipates an increase in sales and a continuous influx of associate signups towards year end.

Donald Steinberg, MCOA’s CEO, stated, “As we start the hempSMART global expansion, it was imperative to have a platform able to facilitate a large number of affiliates with different currencies and languages. This platform provides our affiliates with the latest in marketing software to allow them to take advantage of all social media outlets. With my background in establishing large global marketing and distribution companies, I am confident this platform will allow us to focus on growth. We have a good solid company with an excellent team, and we have developed great industrial hemp based CBD infused products which are garnering acclaim from many sources. In addition, we have an affiliate marketing program that is structured to provide long term residual income from a global marketplace. It is for all of these reasons that I believe our company is now set for long term growth.”

The Company is also highly optimistic about the imminent passage of the Farm Bill by Congress, which will help the Company obtain better banking relationships as well as give more overall awareness to the hempSMART brand and products.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreational use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA Announces New hempSMART(TM) Website and Sales Platform $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Bougainville Ventures (BOG:CSE) – Marijuana M&A: Altria Group Opens the Door to Major Deals $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 10:30 AM on Monday, December 10th, 2018
SPONSOR:  Bougainville Ventures Inc (CSE: BOG) Converting irrigated farmland to greenhouse-equipped farmland. Bougainville does not “touch the plant” and only provides agricultural infrastructure as a landlord for licensed marijuana growers.
————————–

While marijuana stocks have pulled back with the chaos of the broader markets in late 2018, we cannot forget about the countless catalysts that are still out there.

One of the major catalysts involves mergers and acquisitions.

Alcohol companies have had significant interest, for example.

Months ago, Constellation Brands increased its stake in Canopy Growth (CGC) by $4 billion.

That came just months after Constellation first took a 10% stake in Canopy to help create nonalcoholic cannabis-infused drinks and other products.

All, as sales of beer fall in the United States, brewers have begun to bet that legalization of marijuana around the globe, especially the United States, will continue to build momentum and sales of cannabis products will take off.

Molson Coors even listed legal cannabis among the biggest possible risks to its business in its annual shareholder report. Even Coca-Cola expressed some interest at one point.

Now, cigarette makers are jumping into the fray, too.



For example, shares of Cronos (CRON) rocketed higher last week on news that Altria Inc. took at 45% stake in the company for $1.8 billion.

“Investing in Cronos Group as our exclusive partner in the emerging global cannabis category represents an exciting new growth opportunity for Altria,” said Howard Willard, Altria’s CEO, as quoted by CNN.

Talks started, as the tobacco industry comes under pressure, as sales have begun to sharply decline. Just last year, cigarette smoking fell to its lowest point in history. Marijuana sales may bring back some of that lost revenue, though.

According to CNBC, “Counting both legal and black-market sales, the total demand for pot is approximately $52.5 billion, Marijuana Business Daily has reported.”

This could potentially lead to other major M&A deals in the industry following Altria and Constellation news. If nothing else, such major deals provide further evidence that the opportunities in the global marijuana industry are much more than just hype.

For Altria to invest $1.8 billion in a company isn’t small change.

We wouldn’t be shocked to see other pot stocks see further M&A interest moving forward.

Stay tuned for more on potential deals right here.

Source: https://www.chasingmarkets.com/news/15c0e6fba8d6e7/Marijuana_M%26A%3A_Altria_Group_Opens_the_Door_to_Major_Deals


Tags: , ,
Posted in Bougainville Ventures | Comments Off on Bougainville Ventures (BOG:CSE) – Marijuana M&A: Altria Group Opens the Door to Major Deals $CROP.ca $VP.ca NF.ca $MCOA

Tetra Natural Health $TBP.ca Will Deliver 20 containers of #Hemp Energy Drink to Meet Consumer Demand $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:28 AM on Monday, December 3rd, 2018

Logo tetrabiopharma rgb web

  • Announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink,
    • the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.

ORLEANS, Ontario, Dec. 03, 2018 — Tetra Natural Heath, a subsidiary of Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.

Hemp Energy Drink available in 3 flavours: Classic, Mango and Raspberry

Canadian consumers appreciate the qualities of Hemp Energy Drink (www.hempenergydrink.ca) that contains fewer calories and more natural ingredients than other energy drinks, and the product will be available soon everywhere in Canada in three flavors: classic, mango and raspberry.

“We are very pleased with the consumer interest for the Hemp Energy Drink since its launch. Through the agreements we have with our distribution partners, their drive and the strategy we are implementing, Canadians will soon be able to appreciate the three flavors of our cool, fresh, light, natural and 100% legal beverage,” said Richard Giguère, CEO of Tetra Natural Health.

“This 20-container delivery combined with the deployment of our distribution strategy represents an important step in our market development plan for this product over the next year. Thanks to the characteristics of our energy drink and its nutritional elements, we are confident that the Hemp Energy Drink will generate a continued enthusiasm among consumers across Canada,” added Richard Giguère.

Guy Chamberland, President and CEO of Tetra Bio-Pharma stated, “With its Hemp Energy Drink business, Tetra Natural Health will allow the corporation to achieve significant orders and sales over the coming year.  These orders demonstrate that the new team has established a viable natural health and wellness product business that will translate into significant revenues for the coming fiscal year, starting in Q1 2019.”

About Tetra Natural Health
Tetra Natural Health inc. is a subsidiary of Tetra Bio-Pharma inc. that focuses on identification, development and marketing of hemp or cannabis-based natural health products, or cannabinoids-based products authorized for sale by Health Canada.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For more information, please contact:
Richard Giguère
CEO
Tetra Natural Health
T 348-899-7575 ext.210
[email protected]

Media Contact
Daniel Granger
ACJ Communication
T. 514 840-7990
M. 514 232 1556
[email protected]

Charlotte Blanche
T. 514 840-1235 poste 7772
M. 514 914-0593
[email protected]

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ed89d9c7-7309-4cda-88cb-c3033a65805b

Tags: , , , , , ,
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Natural Health $TBP.ca Will Deliver 20 containers of #Hemp Energy Drink to Meet Consumer Demand $AERO $CBDS $CGRW $GBLX

Tetra Bio-Pharma $TBP.ca Closes Financing With Aphria Inc. $APHA $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 5:33 PM on Friday, November 30th, 2018

Logo tetrabiopharma rgb web

  • With increased cash Tetra will ramp up Drug Development Activities
  • Tetra issued to Aphria (6,900,000) units,
    • with each unit being comprised of one Class A common share of Tetra (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), at a price of $1.03 per unit

ORLEANS, Ontario, Nov. 30, 2018 — Tetra Bio-Pharma Inc (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), has closed a private placement of units (the “Private Placement”) with its strategic partner Aphria Inc. (“Aphria”) (TSX: APHA) (NYSE: APHA). Under the Private Placement, Tetra issued to Aphria (6,900,000) units (the “Units”), with each unit being comprised of one Class A common share of Tetra (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), at a price of $1.03 per unit, which is the closing price of the Common Shares on the TSX Venture Exchange on November 28, 2018, for gross proceeds of $7,107,000. Each warrant will entitle Aphria to purchase one full common share at a price of $1.29 per Common Share for a period of 36 months expiring November 2021 subject to acceleration in certain circumstances. As part of the transaction, and in order for Aphria to attain 19.9%, Tetra Co-Founders, Andre Rancourt and Dr. Guy Chamberland, CEO and CSO of Tetra have agreed to sell 5 million shares each to Aphria. Following this sale Dr. Chamberland and Mr. Rancourt will continue to hold 5 million shares each as the company moves forward.

Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “Aphria has been a major strategic partner since the inception of Tetra. Their decision to substantially increase their holding in our company illustrates their confidence in our business model which is focused on taking a pharmaceutical pathway to the commercialization of cannabis and cannabinoid-derived products. The Aphria investment will enable Tetra to increase drug development activities, including in the USA, over the coming months. As for the sale of my shares to Aphria, this divestiture was done to accommodate Aphria and for personal tax and estate planning purposes following the sale of PhytoPain Pharma Inc., earlier this year. I continue to be one of the company’s major shareholders, and I am fully committed to executing Tetra’s business plan.”

“As a leader in the global cannabis industry, Aphria is committed to fostering the research, development and commercialization of medical cannabis treatments and applications with our valued strategic partners,” said Vic Neufeld, CEO of Aphria. “With this investment, we are pleased to deepen our long-standing relationship with Tetra Bio-Pharma as they pursue critical research and clinical trials with the potential to bring notable advances to cannabis and cannabinoid-derived pharmaceutical products.”

About Aphria Inc.
Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality, and innovation. Headquartered in Leamington, Ontario – the green house capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean, and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria dries sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships, and global expansion, with a presence in more than 10 countries across 5 continents.

For more information, visit: www.aphria.ca

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Closes Financing With Aphria Inc. $APHA $AERO $CBDS $CGRW $GBLX

Harvest Update at Marijuana Company of America’s $MCOA CBD Hemp Project in Scio Oregon $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:25 AM on Tuesday, November 27th, 2018

15233 mcoa

  • Provide an update on the harvest at their high yielding CBD hemp project in Scio, Oregon.
  • 2018 Scio cultivation consisted of 33 acres of high yielding CBD hemp (utilizing six different cultivars with an expected CBD content ranging from 6% to 12%), grown in an orchard style cultivation on the property.

Escondido, California–(November 27, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group (CSE: GHG) (OTC Pink: GBHPF)  (FSE: GHG) are pleased to provide an update on the harvest at their high yielding CBD hemp project in Scio, Oregon.

The 2018 Scio cultivation consisted of 33 acres of high yielding CBD hemp (utilizing six different cultivars with an expected CBD content ranging from 6% to 12%), grown in an orchard style cultivation on the property. With the help of near perfect weather in the region that extended the harvest period by several weeks, the hemp crop had the opportunity to grow to full maturity, allowing the team to completely harvest all of the plants before the fall rains began in the valley. For pictures from this season’s cultivation, please visit the Scio project page on MCOA’s corporate website here: http://marijuanacompanyofamerica.com/scio-oregon/

Innovation was the key to overcoming various challenges throughout the year, but the team in Scio was able to find solutions when required. Our team consists of a number of talented crew members trained in a variety of skill sets, including metal fabrication, fine carpentry, and large equipment operation. With the help of a number of knowledgeable advisors, the team set up, built, and operated the project themselves.

The Harvest

Figure 1. 2018 Harvest

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/5634/41264_3b85e8ddf4632858_001full.jpg

This year’s harvest consisted of approximately 37,000 high yielding CBD hemp plants producing 24 tons of biomass. Harvesting this year was done by hand, making it extremely labor intensive and time consuming. However, the team developed a number of solutions that will automate both the harvesting and planting for next year’s crop. Ultimately, the goal is to completely automate these processes, making it more efficient and less costly to complete. The team has now begun working on prototypes to automate the harvesting processes and expect to have machinery ready for use next season.

Drying

Figure 2. Crop Drying

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/5634/41264_3b85e8ddf4632858_003full.jpg

 

Figure 3. Greenhouse Space

To view an enhanced version of Figure 3, please visit:
https://orders.newsfilecorp.com/files/5634/41264_3b85e8ddf4632858_004full.jpg

A number of different drying techniques were employed with this year’s harvest. In the end, “old school” hanging techniques proved to be the most effective and efficient. Drying took place in the farm’s larger 20-foot-high, 4,000 sq. ft. greenhouse which allowed for an increased quantity of plants being dried at any one time. Drying took approximately 36 to 48 hours to achieve the levels required for storage and ultimately extraction. With each successive batch of drying, techniques were improved to increase the volume of biomass being dried in the greenhouse, while decreasing the time that it took to hang and dry it.

Results

The drying process for all of the hemp harvested is now complete, and is stored awaiting further processing. The farm produced 48,000 pounds of dried biomass, which is stockpiled in quarter ton super sacks, stacked three bags high and requiring approximately 4,000 sq. ft. of storage space. Despite the late start in planting this season, the hemp plants still achieved sufficient size to produce the anticipated quantity of biomass. It is expected that in 2019, planting will begin June 1st giving the hemp an addition 30-45 days of growing time. This will produce much larger plants, resulting in significantly larger quantities of biomass.

Further Processing

The Partners acquired a hammermill to complete the next level of processing, prior to the biomass going for extraction of the cannabinoids. Processing will begin shortly, once electrical work is complete to run the hammermill. This next level of processing will not only prepare the biomass for extraction of cannabinoids, but will also reduce the storage space requirements by more than 50% as the bulk of the plants is reduced in size.

Extraction

The Partners are currently exploring opportunities to joint venture with others that have expertise in the cannabinoid extraction business, so that an extraction facility can be set up onsite to process this year’s harvest. Biomass is currently selling for between US$3.00 and US$4.00 per pound. By taking the biomass to the next level of processing, further value will be created.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Global Hemp Group Inc.

Global Hemp Group Inc. (CSE: GHG) (OTC: GBHPF) (FSE: GHG), is focused on a multi-phased strategy to build a strong presence in the industrial hemp industry in both Canada and the United States. The Company is headquartered in Vancouver, British Columbia, with hemp cultivation operations in New Brunswick and Oregon. The first phase of this strategy is to develop hemp cultivation with the objective of extracting cannabinoids (CBD, CBG, CBN & CBC) and creating a near term revenue stream that will allow the Company to expand and develop successive phases of the strategy. The second phase of the plan will focus on the development of value-added industrial hemp products utilizing the processing of the whole hemp plant, as envisioned in the Company’s Hemp Agro-Industrial Zone (HAIZ) strategy.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWire/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , ,
Posted in Marijuana Company of America | Comments Off on Harvest Update at Marijuana Company of America’s $MCOA CBD Hemp Project in Scio Oregon $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Bolsters Intellectual Property Position and Product Pipeline $AERO $CBDS $CGRW $APH.ca

Posted by AGORACOM-JC at 8:20 AM on Tuesday, November 27th, 2018

Logo tetrabiopharma rgb web

  • Announced the signing of a non-binding term sheet to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications
  • Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition.

Seeks joint venture with Altus Formulation Inc. – a drug formulation and development company with patented technologies

ORLEANS, Ontario, Nov. 27, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF), and Altus Formulation Inc. (“Altus”) today announced the signing of a non-binding term sheet (“Term Sheet“) to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications. Altus has three distinct drug delivery technologies that will provide Tetra with significant strategic advantages over the competition. These include IntellitabTM abuse deterrent technology, FlexitabTM breakable sustained release tablet technology and SmartCelleTM nano-technology. SmartCelle’s ability to enhance the solubility of our THC and CBD products permits increased oral absorption and enables parenteral delivery. All platforms are protected by patents in force globally.

The Proposed Joint-Venture will provide Tetra Bio-Pharma with:

  • Increased intellectual property protection for products developed under the joint venture;
  • Access to abuse deterrent technology to minimize non-medical use of cannabinoids;
  • An enhanced development pipeline addressing new therapeutic areas;
  • Opportunities for disease-appropriate delivery including intranasal and intravenous delivery; and
  • Increased oral drug absorption with immediate and extended release products.

Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma stated, “We are extremely excited about the creation of this joint venture as Altus brings many advantages to the table that will benefit our patients, their care providers and add tremendous value to the products being developed together. Their drug delivery technology will significantly strengthen our intellectual property portfolio.”

The White House Executive Office of the President of the United States along with several U.S. Federal agencies are encouraging pharmaceutical manufacturers to develop abuse-deterrent technologies. The Altus intellectual property will allow Tetra to bring formulations containing THC to market with a product label that clearly indicates its abuse-deterrence feature.

“This will be a major breakthrough for marketing THC drugs with opioid reduction claims at a time when society and the medical community are battling the epidemic abuse of opioids,” said Dr. Chamberland.

“We were highly impressed by Tetra’s science-driven approach to cannabinoid research and their proven ability to develop valuable medicines in this largely untapped new space,” said Dr. Damon Smith, CEO of Altus Formulation. “We greatly look forward to working with them and to bringing a range of life-changing new products to our patients.”

About Altus Formulation Inc.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost effective new products for its partners and their patents. With a focus on safer to use formulations, Altus’ technologies also include SmartCelle technologies for intravenous or oral delivery of low solubility large and small molecules.

For more information, please visit www.altusformulation.com

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Health Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Altus Formulation Inc.
Damon Smith
CEO
514-883-3447

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]		 Stephanie Engel
416-425-9143 ext. 209
[email protected]

 

Tags: , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Bolsters Intellectual Property Position and Product Pipeline $AERO $CBDS $CGRW $APH.ca

Tetra Bio-Pharma’s $TBP.ca Dr. Chamberland Goes to Washington! $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:09 AM on Monday, November 26th, 2018

Logo tetrabiopharma rgb web

  • Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
  • Meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

ORLEANS, Ontario, Nov. 26, 2018 – Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to update the market that Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.

The meetings, scheduled for November 26th and 27th, have a mutually beneficial purpose, namely expanding Tetra’s existing work with Health Canada and the FDA in the United States as well as briefing the Senators on Tetra Bio-Pharma’s unique approach which combines the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

Tetra Bio-Pharma is the only company in North America, in addition to GW Pharmaceuticals, to work with both the FDA and Health Canada on clinical trial programs investigating cannabis and cannabinoid-based products for medical use. Tetra is currently recruiting patients for several clinical trials, including advanced cancer pain and a head to head trial investigating cannabis versus fentanyl in the treatment of breakthrough cancer pain, with the ultimate goal of reducing opioid use.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of the products mentioned above and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 226		 Stephanie Engel
[email protected]
416-425-9143 ext. 209

Tags: , , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma’s $TBP.ca Dr. Chamberland Goes to Washington! $AERO $CBDS $CGRW $APH.ca $GBLX

North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:18 PM on Thursday, November 22nd, 2018

Northbud large

  • Construction cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction
  • Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete
  • Company expects the building to be operational in Q1 2019

TORONTO, Nov. 22, 2018 — North Bud Farms Inc. (CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders with an update on our corporate activities.

Construction of our Cannabis Production Facility in Low, Quebec
NORTHBUD is pleased to update shareholders that the construction of our cannabis production facility in Low, Quebec remains on schedule as per the timeline provided from our builder NGA Construction. Erecting of the steel structure began on the 19th of November and is expected to take approximately 30 days to complete. We expect the building to be operational in Q1 2019. Please follow our social media channels for video updates of the facility construction (https://vimeo.com/302330795) and branding out reach.

Cannabis Act Application
Migration of the application to the Cannabis Licensing Tracking System (“CLTS”) has begun in collaboration with Cannabis Consulting Inc., one of the leading consultancy firms in the industry.

Update on Janey’s Inc. Acquisition
NORTHBUD and Janey’s continue to work on finalizing the acquisition agreement to include additional product segments. To date Janey’s has fulfilled multiple orders to the Ontario Cannabis Store and intends to expand its offering in the upcoming product calls.

Corporate Initiatives
NORTHBUD wishes to inform shareholders that its Board of Directors has approved management’s request to explore business opportunities in other international jurisdictions.

“This development represents an evolution in our business since going public and we feel it is important to update shareholders and potential shareholders that we will be actively pursuing international opportunities that we believe are complementary to our core business and that should create value for shareholders as we expand NORTHBUD’s global presence,” said Ryan Brown, CEO of North Bud Farms Inc.

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).   North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.

For more information visit: www.northbud.com.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Featured, North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Provides Corporate Update $ACB $WEED.ca $HIP.ca

Expect Supply Issues for Canadian Pot On Stronger than Expected Demand – SPONSOR: North Bud Farms $NBUD.ca

Posted by AGORACOM-JC at 2:59 PM on Thursday, November 22nd, 2018

SPONSOR: North Bud Farms Inc. (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Click Here For More Information

  • As Canada battles a nationwide marijuana shortage, Massachusetts dispensaries opened to recreational users on Tuesday.
  • Regulatory bottlenecks and unforeseen demand have caused disruptions in Canada’s marijuana supply ー but don’t expect the trouble to cease next year.

By Chloe Aiello

As Canada battles a nationwide marijuana shortage, Massachusetts dispensaries opened to recreational users on Tuesday.

Regulatory bottlenecks and unforeseen demand have caused disruptions in Canada’s marijuana supply ー but don’t expect the trouble to cease next year.

Khurram Malik, CEO of cannabis supplier Biome Grow, said he expects current supply issues to resolve soon, but he anticipates disorder in Canadian cannabis well into 2019.

Next year “is going to be a period of intermittent supply issues. What I mean by intermittent is you may have your favorite strain available one day, but not potentially two or three weeks down the line, and you’ll have to wait again for it,” Malik told Cheddar on Tuesday.

“But it won’t be a sky-is-falling scenario, like we’re seeing right now, where you just have completely empty store shelves in a variety of provinces,” he added.

Cannabis shortages across Canada have forced dispensaries to shutter only weeks out from recreational marijuana legalization. The shortages threaten to undermine legalization’s aim of quashing the illegal drug trade, as some frustrated customers return to their black market dealers, The New York Times reported.

Unexpected demand has contributed to bare shelves across the country, but so too have functional issues and regulatory red tape.

Issues ranging from delays in sales permits to cultivation licensing to shortages in excise stamps and packaging have contributed to the problem, Malik said.

“The problem in Canada … is it takes a while from a facility coming online to actually getting product out the door. There is a lot of regulatory things you have to jump through to prove you can actually start selling cannabis,” Malik said. “We don’t expect complete supply and demand to be sort of normalized until late 2019 or early 2020. Until then, you’ll see these intermittent issues.”

One day out, Massachusetts’ adult use marijuana supply seems to be fine, but Boston.com reporter Nikolas DeCosta-Kilpa said there has been some worry about supply issues, as the dispensaries work to build up their inventories.

“In Massachusetts, at least initially, the retail stores that are going to get into the adult use marijuana business are existing medical marijuana dispensaries, and they legally have to keep a certain percentage … of their inventory for their medical patients,” DeCosta-Kilpa said.

Massachusetts became the first East Coast state to legalize recreational marijuana in the U.S. Customers over 21 waited up to three hours at a time to ride the Massachusetts green wave, which kicked off at the only two dispensaries currently licensed to sell. Cultivate in Leicester, Mass., served served more than 500 customers within the first two hours of recreational sales, according to Boston.com.

Source: https://cheddar.com/videos/canada-faces-cannabis-supply-shortage-after-legalization

Tags: , , , , ,
Posted in All Recent Posts, North Bud Farms Inc | Comments Off on Expect Supply Issues for Canadian Pot On Stronger than Expected Demand – SPONSOR: North Bud Farms $NBUD.ca

CLIENT FEATURE: North Bud Farms $NBUD.ca sustainable low cost, high quality cannabinoid production and procurement $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 12:26 PM on Wednesday, November 21st, 2018

WHY NORTHBUD FARMS?

  • Canadian regulatory door for CIP (Cannabinoid Infused Products) is opening in 2019
    As shown in other legal jurisdictions (Colorado, Washington, Nevada, California)
  • Infused products sector has become the highest margin segment of the industry
  • Positioned to be a raw input producer for this space
  • Currently working with multiple food, beverage and science companies to provide safe standardized cannabinoid infused raw inputs for large scale GMP manufacturing of products
  • Announced Creation of “1017” Distribution and Signing of a LOI to Acquire Janey’s Cannabis Line

THE OPPORTUNITY

  • Acquired late stage ACMPR applicant GrowPros
    MMP from Tetra Bio-Pharma (TSXV: TBP)
  • GrowPros MMP application was submitted in November 2014 and is currently in the ‘Confirmation of Readiness’ stage.
  • Phase 1 is located on 95 acres of agricultural farmland in Low, Québec.
  • Option exists to acquire more land if needed
  • Facility will focus on GMP (higher production grade) pharma-grade cultivation and food-grade extracted inputs

 NORTHBUD October Construction Update. Everything is on schedule!

LOCATION

SITE DETAILS: LOW COST INFRASTRUCTURE

Construction of Facility

NORTHBUD and its team have been hard at work finalizing some minor design changes. NORTHBUD has received a detailed timeline for construction from our builder, NGA Construction Inc., and is on schedule to have the facility completed and an evidence package submitted to Health Canada in Q1 2019.

All infrastructure implementation has been completed and physical facility construction has begun.

ACMPR Application:

NORTHBUD, through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR).  In this regard, NORTHBUD has engaged Cannabis Compliance Inc. to assist in the migration of the ACMPR application to the CLTS which went into effect after the implementation of the Cannabis Act on October 17, 2018. NORTHBUD will be making amendments in order to take advantage of favourable changes that have been implemented under the Cannabis Act.

Hub On AGORACOM

FULL DISCLOSURE: North Bud Farms is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, North Bud Farms Inc | Comments Off on CLIENT FEATURE: North Bud Farms $NBUD.ca sustainable low cost, high quality cannabinoid production and procurement $ACB $WEED.ca $HIP.ca

« Older Entries
Newer Entries »